We are live on ! Find out more
WIM

Woodford Investment Management Portfolio holdings

AUM $310M
1-Year Est. Return 17.41%
This Fund
S&P 500
This Quarter Est. Return
-3.42%
1 Year Est. Return
-17.41%
3 Year Est. Return
-27.14%
5 Year Est. Return
+68.29%
10 Year Est. Return
–
AUM
$2.08B
AUM Growth
-$396M
Cap. Flow
-$285M
Cap. Flow %
-13.71%
Top 10 Hldgs %
100%
Holding
8
New
–
Increased
5
Reduced
2
Closed
1

Top Buys

Rank Stock Value
1
TBPH icon
Theravance Biopharma
TBPH
+$34.1M
2
BIIB icon
Biogen
BIIB
+$23.2M
3
ABBV icon
AbbVie
ABBV
+$12.4M
4
GILD icon
Gilead Sciences
GILD
+$9.48M
5
PRTA icon
Prothena Corp
PRTA
+$483K

Top Sells

Rank Stock Value
1
RAI
Reynolds American Inc
RAI
+$359M
2
ALKS icon
Alkermes
ALKS
+$5.23M
3
NWBO
Northwest Biotherapeutics, Inc. Common stock
NWBO
+$554K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
2 Consumer Staples 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ABBV icon
1
AbbVie
ABBV
$435B
$703M 33.86%
11,232,758
+202,958
+2% +$12.4M
PRTA icon
2
Prothena Corp
PRTA
$450M
$507M 24.42%
10,310,511
+8,760
+0.1% +$483K
ALKS icon
3
Alkermes
ALKS
$8.25B
$414M 19.94%
7,451,128
-97,905
-1% -$5.23M
TBPH icon
4
Theravance Biopharma
TBPH
$877M
$335M 16.13%
10,507,608
+1,100,471
+12% +$34.1M
BIIB icon
5
Biogen
BIIB
$30.7B
$64.9M 3.13%
248,530
+78,100
+46% +$23.2M
GILD icon
6
Gilead Sciences
GILD
$165B
$44M 2.12%
614,300
+127,500
+26% +$9.48M
NWBO
7
DELISTED
Northwest Biotherapeutics, Inc. Common stock
NWBO
$8.64M 0.42%
24,815,028
-1,100,909
-4% -$554K
RAI
8
DELISTED
Reynolds American Inc
RAI
– –
-7,608,324
Closed -$359M

Similar funds

LCM
Lucha Capital Management San Francisco, California $327M AUM 2.87% 1-Year Est. Return
GWA
Guidant Wealth Advisors Palatine, Illinois $269M AUM 2.79% 1-Year Est. Return
NC
Northpointe Capital Bloomfield Hills, Michigan $258M AUM 1.97% 1-Year Est. Return
IPC
Invesco Private Capital New York $365M AUM 8.08% 1-Year Est. Return
AEPG
American Economic Planning Group Warren, New Jersey $367M AUM 2.51% 1-Year Est. Return
AR
Argyll Research Wilmington, Delaware $377M AUM 4.86% 1-Year Est. Return
KCM
Keywise Capital Management Grand Cayman, Cayman Islands $220M AUM 21.27% 1-Year Est. Return
COI
Capital One Investing Mclean, Virginia $430M AUM 3.49% 1-Year Est. Return

Woodford Investment Management's Q4 2016 Portfolio in Review

As of Q4 2016, Woodford Investment Management held 8 positions worth $2.08B, down 16% from $2.47B the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Woodford Investment Management withdrew a net $285M in Q4 2016, closing 1 position and reducing 2 holdings. Its most notable exit was Reynolds American Inc, an estimated $359M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 85% a quarter earlier, followed by Consumer Staples.

Against the trend, Woodford Investment Management added an estimated $34.1M to Theravance Biopharma.

  • Woodford Investment Management added most to Theravance Biopharma in Q4 2016, an estimated $34.1M increase.
  • Woodford Investment Management's biggest Q4 2016 reduction was Alkermes, cutting an estimated $5.23M.
  • Woodford Investment Management fully exited Reynolds American Inc in Q4 2016, selling an estimated $359M.
  • Woodford Investment Management's ten largest holdings make up 100% of its $2.08B portfolio in Q4 2016.
  • Woodford Investment Management opened 0 new positions and closed 1 in Q4 2016.
  • Woodford Investment Management's portfolio value fell 16% quarter-over-quarter to $2.08B.

Based on Woodford Investment Management's 13F filing for Q4 2016, filed 14 Feb 2017.